Switzerland-based pharmaceutical company Novartis announced Tuesday that it has lost its appeal of a competition fine issued by Italian officials for anticompetitive conduct.
According to reports, a regional court in Italy upheld fines issued to Novartis and its rival Roche for anticompetitive conduct; the nation’s Competition Authority sanctioned the companies last March after finding the firms had colluded to prevent market entry of a cancer drug for use as an eye disease treatment. The companies were fined $226 million, reports say.
While the fines were upheld, Novartis still denies the decision. “Novartis firmly rejects the accusations of anticompetitive practices and any allegations of anticompetitive behavior are unfounded and without merit,” the company said in a statement, adding that the company will appeal this decision as well.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Croatian Supermarket Chain Tommy Cleared to Acquire Brodokomerc Nova
Oct 13, 2024 by
CPI
X and Unilever Settle Antitrust Dispute, Continuing Partnership
Oct 13, 2024 by
CPI
Federal Judge Allows Antitrust Claims Against GoDaddy to Proceed
Oct 13, 2024 by
CPI
Court Ruling Opens Door for Microsoft to Sell Xbox Games on Android Without Google’s Cut
Oct 13, 2024 by
CPI
Realtors Appeal to Supreme Court Over DOJ’s Investigation into Antitrust Violations
Oct 13, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh